Lupin Launches Mycophenolic Acid Delayed-Release Tablets USP

Pharma major Lupin Limited (Lupin) announced the launch of Mycophenolic Acid Delayed-Release Tablets USP, 180 mg and 360 mg. Lupin’s alliance partner Concord Biotech Limited (Concord) had received an approval from the United States Food and Drug Administration (U.S. FDA) earlier.

Mycophenolic Acid Delayed-Release Tablets USP, 180 mg and 360 mg, is the generic equivalent of Myfortic® Delayed-Release Tablets, 180 mg and 360 mg, of Novartis Pharmaceuticals Corporation, and are indicated for:

– Prophylaxis of organ rejection in adult patients receiving kidney transplants and in pediatric patients at least 5 years of age and older who are at least 6 months post kidney transplant.

– Use in combination with cyclosporine and corticosteroids.

Mycophenolic Acid Delayed-Release Tablets USP (RLD: Myfortic® ) had an annualsales of approximately USD 156 million in the U.S. (IQVIA MAT February 2020).

Shares of LUPIN LTD. was last trading in BSE at Rs.654.8 as compared to the previous close of Rs. 579.2. The total number of shares traded during the day was 231973 in over 9571 trades.

The stock hit an intraday high of Rs. 665 and intraday low of 578.6. The net turnover during the day was Rs. 147381817.-Equity Bulls